172 related articles for article (PubMed ID: 36215854)
1. Synthesis and anticancer activity of novel histone deacetylase inhibitors that inhibit autophagy and induce apoptosis.
Mo H; Zhang R; Chen Y; Li S; Wang Y; Zou W; Lin Q; Zhao DG; Du Y; Zhang K; Ma YY
Eur J Med Chem; 2022 Dec; 243():114705. PubMed ID: 36215854
[TBL] [Abstract][Full Text] [Related]
2. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
3. Exploration of certain 1,3-oxazole- and 1,3-thiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
Anh DT; Hai PT; Huong LT; Park EJ; Jun HW; Kang JS; Kwon JH; Dung DTM; Anh VT; Hue VTM; Han SB; Nam NH
Bioorg Chem; 2020 Aug; 101():103988. PubMed ID: 32534346
[TBL] [Abstract][Full Text] [Related]
4. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
[TBL] [Abstract][Full Text] [Related]
5. Novel Suberoylanilide Hydroxamic Acid Analogs Inhibit Angiogenesis and Induce Apoptosis in Breast Cancer Cells.
Moku G; Vangala S; Yakati V; Gali CC; Saha S; Madamsetty VS; Vyas A
Anticancer Agents Med Chem; 2022; 22(5):914-925. PubMed ID: 34488592
[TBL] [Abstract][Full Text] [Related]
6. Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.
Shi XY; Ding W; Li TQ; Zhang YX; Zhao SC
Med Sci Monit; 2017 Dec; 23():5793-5802. PubMed ID: 29211704
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS
Clin Cancer Res; 2006 Sep; 12(17):5199-206. PubMed ID: 16951239
[TBL] [Abstract][Full Text] [Related]
8. Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells.
Jeon HS; Ahn MY; Park JH; Kim TH; Chun P; Kim WH; Kim J; Moon HR; Jung JH; Kim HS
Int J Oncol; 2010 Aug; 37(2):419-28. PubMed ID: 20596669
[TBL] [Abstract][Full Text] [Related]
9. Anticancer effects of the HDAC inhibitor, 3β,6β‑dihydroxyurs‑12‑en‑27‑oic acid, in MCF‑7 breast cancer cells via the inhibition of Akt/mTOR pathways.
Lim JS; Kyung SY; Jeon Y; Kim IS; Kwak JH; Kim HS
Oncol Rep; 2023 Feb; 49(2):. PubMed ID: 36633143
[No Abstract] [Full Text] [Related]
10. Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways.
Ling Y; Li Y; Zhu R; Qian J; Liu J; Gao W; Meng C; Miao J; Xiong B; Qiu X; Ling C; Dai H; Zhang Y
J Nat Prod; 2019 Jun; 82(6):1442-1450. PubMed ID: 31120744
[TBL] [Abstract][Full Text] [Related]
11. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
[TBL] [Abstract][Full Text] [Related]
12. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
13. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
14. A novel harmine derivative, N-(4-(hydroxycarbamoyl)benzyl)-1-(4- methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxamide (HBC), as histone deacetylase inhibitor: in vitro antiproliferation, apoptosis induction, cell cycle arrest, and antimetastatic effects.
Miao JF; Peng YF; Chen S; Gao WJ; Yang QX; Zhu P; Guo J; Tao J; Luo L; Zhang Y; Ling Y
Eur J Pharmacol; 2018 Apr; 824():78-88. PubMed ID: 29428472
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
Yang Z; Shen M; Tang M; Zhang W; Cui X; Zhang Z; Pei H; Li Y; Hu M; Bai P; Chen L
Eur J Med Chem; 2019 Sep; 178():116-130. PubMed ID: 31177073
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H
Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163
[TBL] [Abstract][Full Text] [Related]
18. The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells.
Chen S; Zhao Y; Gou WF; Zhao S; Takano Y; Zheng HC
PLoS One; 2013; 8(11):e79781. PubMed ID: 24236158
[TBL] [Abstract][Full Text] [Related]
19. A novel suberoylanilide hydroxamic acid histone deacetylase inhibitor derivative, N25, exhibiting improved antitumor activity in both human U251 and H460 cells.
Zhang S; Huang WB; Wu L; Wang LY; Ye LB; Feng BH
Asian Pac J Cancer Prev; 2014; 15(10):4331-8. PubMed ID: 24935393
[TBL] [Abstract][Full Text] [Related]
20. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance.
Carew JS; Nawrocki ST; Kahue CN; Zhang H; Yang C; Chung L; Houghton JA; Huang P; Giles FJ; Cleveland JL
Blood; 2007 Jul; 110(1):313-22. PubMed ID: 17363733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]